Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents;Algoritmo Latino-Americano para tratamento da esclerose múltipla remitente-recorrente utilizando drogas modificadoras da doença

Arquivos de Neuro-Psiquiatria

Volumn 70, Issue 10, 2012, Pages 799-806

  Finkelsztejn, Alessandro ^a   Gabbai, Alberto Alain ^b   Fragoso, Yara Dadalti ^c   Carrá, Adriana ^d   Macías Islas, Miguel Angel ^e   Arcega Revilla, Raul ^f   García Bonitto, Juan ^g   Oehninger Gatti, Carlos Luis ^h   Orozco Escobar, Geraldine ⁱ   Tarulla, Adriana ^j   Vergara, Fernando ^k   Vizcarra, Darwin ^l  

^a UNIVERSITY OF CAXIAS DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

^d HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^e UNIVERSITY OF GUADALAJARA   (Mexico)

^f HOSPITAL DE ESPECIALIDADES   (Mexico)

^g Universidad de la Republica Oriental del Uruguay ^*

^h UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

ⁱ Department of Demyelinating Diseases   (Venezuela)

^j INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^k UNIVERSIDAD DE LOS ANDES   (Chile)

^l UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

more..

Author keywords

Latin America; Multiple sclerosis; Treatment

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GADOLINIUM; GLATIRAMER; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; RITUXIMAB;

ALGORITHM; ALOPECIA; AMENORRHEA; ARGENTINA; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD CELL COUNT; BRADYCARDIA; BRAIN ATROPHY; BRAZIL; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); CYSTITIS; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EXPANDED DISABILITY STATUS SCALE; HEMATOLOGIC DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFECTION; LEUKEMIA; LOW DRUG DOSE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; RHEUMATOID ARTHRITIS; SEPSIS; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIC PURPURA; THYROIDITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS DETECTION;

EID: 84867845464     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2012001000009     Document Type: Article

References (38)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
2. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2010;10:520-529.
3. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101.
4. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-1801.
5. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-238.
6. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338-348.
7. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688.
8. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400.
9. Rieckmann P, Heidenreich F, Sailer M, et al. Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 2012;5:3-12.
10. Le Page, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79:52-56.
11. Cocco E, Marchi P, Sardu C, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007;13:975-980.
12. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 4, 2005:CD002127.
13. Esposito F, Radaelli M, Martinelli V, et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2010;16:1490-1499.
14. Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting. Clin Neurol Neurosurg 2010;112:876-882.
15. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009;15:505-508.
16. Martinelli V, Radaelli M, Straffi L, Rodegher M, Comi G. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 2009;30:S167-S170.
17. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-1470.
18. Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2008;266:25-30.
19. Gray OM, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2;2004:CD003208.
20. Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006;12:507-510.
21. García Bonitto JR, Sánchez Múnera JL. Guía neurológica 9: esclerosis múltiple. Bogotá: Asociación Colombiana de Neurología; 2009.
22. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol 2007;254:1723-1728.
23. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 4; 2007:CD003982.
24. La Mantia, Mascoli N, Milanese C. Azathioprine. Safety profile in multiple sclerosis patients. Neurol Sci 2007;28:299-303.
25. La Mantia, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 1; 2007:CD002819.
26. Gladstone DE, Peyster R, Baron E, et al. High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis: 2-Year Follow-up (Investigational New Drug No. 65863). Am J Ther 2011;18:23-30.
27. Rinaldi L, Perini P, Calabrese M, Gallo P. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. Neurol Sci 2009;30:S171-S173.
28. Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008;65:1044-1051.
29. Schwartzman RJ, Simpkins N, Alexander GM, et al. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther 2009;15:118-127.
30. Tenembaum S. Therapy of multiple sclerosis in children and adolescents. Clin Neurol Neurosurg 2010;112:633-640.
31. Ghezzi A, Amato MP, Annovazzi P, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci 2009;30:193-199.
32. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008;65:1655-1658.
33. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 2009;13:67-71.
34. Karenfort M, Kieseier BC, Tibussek D, Assmann B, Schaper J, Mayatepek E. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol 2009;51:159-163.
35. Makhani N, Gorman M, Branson H, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009;72:2076-2082.
36. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology 2010;27:S3-S7.
37. Brooks JRR, Borella M, Fragoso YD. Assessment of cognition using the Rao's Brief Repeatable Battery of Neuropsychological Tests on a group of Brazilian patients with multiple sclerosis. Arq Neuropsiquiatr. 2011;69:887-891.
38. Rodrigues DN, Paes RA, Vasconcelos CC, Landeira-Fernandez J, Papais-Alvarenga RM. Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis. Arq Neuropsiquiatr 2011;69:590-595.